The Shifting Paradigms With Perioperative Treatment Strategies in Early-Stage NSCLC

Author(s):

Benjamin P. Levy, MD,Misty D. Shields, MD, PhD

Panelists discuss how recent data from KEYNOTE-671, AEGEAN, and CheckMate 77T reinforce neoadjuvant therapy’s efficacy in early-stage non–small cell lung cancer (NSCLC), showing consistent survival benefits. In contrast, adjuvant data remain conflicting, limiting its role. Neoadjuvant therapy should be prioritized, with adjuvant therapy reserved for select high-risk patients.

EP: 1.An Expert Insights on Recent Advancements in LS-SCLC

EP: 2.The Key Updates in the Treatment of ES-SCLC

EP: 3.An Expert Perspectives on Tarlatamab in ES-SCLC

EP: 4.Looking Ahead With SCLC: ADCs and Other Novel Agents

Now Viewing

EP: 5.The Shifting Paradigms With Perioperative Treatment Strategies in Early-Stage NSCLC

EP: 6.Personalizing Adjuvant Targeted Therapies in Early-Stage NSCLC

EP: 7.The New Targeted Approaches in Unresectable Early-Stage NSCL

EP: 8.Navigating the New Treatment Options in the Frontline Management of Advanced EGFR-Mutant NSCLC

Video content above is prompted by the following:

What are your perspectives on the latest efficacy, safety data, and recent approvals in early-stage NSCLC treatment, and how have these influenced your clinical practice?
KEYNOTE-671: Wakelee H, et al. NEJM. 2023;389:491-503.
AEGEAN: Heymach JV, et al. WCLC 2024. Abs OA13.03. (Approval August 2024)
CheckMate 77T: Spicer J, et al. ESMO 2024. LBA50(Approval October 2024)
Briefly comment on the conflicting data in the adjuvant setting and contrast that with the consistency demonstrated in the neoadjuvant setting, and discuss how you translate this into your clinical practice.
Should neoadjuvant therapy be recommended for all patients who do not proceed directly to surgery?
In which patients should adjuvant therapy be added, and what is the remaining role for adjuvant therapy alone?

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!